indomethacin and Bacterial Disease studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Research Excerpts

Excerpt	Relevance	Reference
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia."	7.67	Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987)
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia."	3.67	Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987)
"Pretreatment with indomethacin significantly decreased the proportion of fetal death from 83% to < 25% in mice injected with 10 micrograms of LPS."	1.29	Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. ( Branch, DW; Dudley, DJ; Edwin, SS; Mitchell, MD; Silver, RM; Simmons, DL; Trautman, MS, 1995)
"Indomethacin sodium promotes closure of the patent ductus arteriosus in premature infants."	1.27	Indomethacin-associated sepsis in very-low-birth-weight infants. ( Eisenfeld, LI; Herson, VC; Krause, PJ; Maderazo, EG; Pontius, L, 1988)

Research

Studies (22)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

Fetal Outcome 4 - Incidence of Fetal Loss

Fetal Outcome 5 - Incidence of Spontaneous Abortion

Fetal Outcome 6 - Incidence of All Stillbirth

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (54.55)	18.7374
1990's	6 (27.27)	18.2507
2000's	2 (9.09)	29.6817
2010's	2 (9.09)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Shelke, SH	1
Mhaske, PC	1
Nandave, M	1
Narkhade, S	1
Walhekar, NM	1
Bobade, VD	1
McElroy, SJ	1
Gordon, PV	1
Attridge, JT	1
Porras, M	1
Martín, MT	1
Soler, M	1
Vergara, P	1
Burke, V	1
Gracey, M	1
Korman, SH	1
Berant, M	1
Alon, U	1
Horan, TD	1
English, D	1
McPherson, TA	1
Friedman, CA	1
Parks, BR	1
Rawson, JE	1
Serwer, GA	1
Anderson, PA	1
Meyer, TA	1
Wang, J	1
Tiao, GM	1
Ogle, CK	2
Fischer, JE	3
Hasselgren, PO	3
Silver, RM	1
Edwin, SS	1
Trautman, MS	1
Simmons, DL	1
Branch, DW	1
Dudley, DJ	1
Mitchell, MD	1
Ohno, Y	1
Kasugai, M	1
Kurauchi, O	1
Mizutani, S	1
Tomoda, Y	1
West, MA	1
Manthei, R	1
Bubrick, MP	1
Newton, ER	1
Shields, L	1
Ridgway, LE	1
Berkus, MD	1
Elliott, BD	1
Horgan, PG	1
Mannick, JA	1
Dubravec, DB	1
Rodrick, ML	1
Nakai, S	1
Hirai, Y	1
Kramarev, SA	1
Hanly, PJ	1
Roberts, D	1
Dobson, K	1
Light, RB	1
Bihari, DJ	1
Salzer, HR	1
Salzer-Muhar, U	1
Pollak, A	1
Weninger, M	1
Warner, BW	2
Hummel, RP	2
James, JH	2
Herson, VC	1
Krause, PJ	1
Eisenfeld, LI	1
Pontius, L	1
Maderazo, EG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]		11,976 participants (Actual)	Interventional	2016-03-23	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Intervention Arm	189
Placebo Arm	230

Intervention	Participants (Count of Participants)
Intervention Arm	1078
Placebo Arm	1153

Intervention	Participants (Count of Participants)
Intervention Arm	78
Placebo Arm	101

Intervention	Participants (Count of Participants)
Intervention Arm	303
Placebo Arm	353

Intervention	Participants (Count of Participants)
Intervention Arm	134
Placebo Arm	152

Intervention	Participants (Count of Participants)
Intervention Arm	141
Placebo Arm	166

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

Incidence of Hypertensive Disorders of Pregnancy

Intervention	Participants (Count of Participants)
Intervention Arm	42
Placebo Arm	30

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

Incidence of Perinatal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	352
Placebo Arm	325

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Incidence of Preterm Birth

Intervention	Participants (Count of Participants)
Intervention Arm	264
Placebo Arm	309

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

Incidence of Small for Gestational Age (SGA)

Intervention	Participants (Count of Participants)
Intervention Arm	668
Placebo Arm	754

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 1 - Incidence of Vaginal Bleeding

Intervention	Participants (Count of Participants)
Intervention Arm	1506
Placebo Arm	1564

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	214
Placebo Arm	246

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	26
Placebo Arm	25

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 4 - Incidence of Maternal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	54
Placebo Arm	43

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 5 - Incidence of Late Abortion

Intervention	Participants (Count of Participants)
Intervention Arm	9
Placebo Arm	12

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 6 - Change in Maternal Hemoglobin

Intervention	Participants (Count of Participants)
Intervention Arm	23
Placebo Arm	30

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Intervention	Participants (Count of Participants)
Intervention Arm	290
Placebo Arm	333

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Article	Year
Understanding clinical literature relevant to spontaneous intestinal perforations. American journal of perinatology, 2009, Volume: 26, Issue:4 Topics: Acute Disease; Bacterial Infections; Critical Care; Dexamethasone; Drug Therapy, Combination; Female	2009
Review: prostaglandins in diarrheal states. Israel journal of medical sciences, 1981, Volume: 17, Issue:12 Topics: Aspirin; Bacterial Infections; Child; Cholera Toxin; Colonic Diseases; Cyclic AMP; Diarrhea; Dinopro	1981

Article	Year
Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents. Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Bacterial Infections; Carrageena	2012
Unraveling the enigma that is neonatal necrotizing enterocolitis. Journal of perinatology : official journal of the California Perinatal Association, 2014, Volume: 34, Issue:10 Topics: Bacterial Infections; Dexamethasone; Female; Humans; Indomethacin; Infant, Very Low Birth Weight; In	2014
Intestinal motor disorders associated with cyclical bacterial overgrowth in a rat model of enteritis. American journal of physiology. Gastrointestinal and liver physiology, 2004, Volume: 287, Issue:1 Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Bacterial Infections; Bac	2004
Studies with enterotoxigenic microorganisms: effects of candidate antidiarrhoeals in experimental animals in vivo. Journal of pediatric gastroenterology and nutrition, 1984, Volume: 3, Issue:4 Topics: Aluminum Hydroxide; Animals; Antidiarrheals; Aspirin; Bacterial Infections; Charcoal; Chlorpromazine	1984
Association of neutrophil chemiluminescence with microbicidal activity. Clinical immunology and immunopathology, 1982, Volume: 22, Issue:2 Topics: 4-Chloromercuribenzenesulfonate; Ascorbic Acid; Bacterial Infections; Blood Bactericidal Activity; C	1982
Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. Developmental pharmacology and therapeutics, 1982, Volume: 4, Issue:1-2 Topics: Bacterial Infections; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Half-Life; Humans	1982
Sepsis and endotoxemia stimulate intestinal interleukin-6 production. Surgery, 1995, Volume: 118, Issue:2 Topics: Animals; Bacterial Infections; Base Sequence; Dinoprostone; Endotoxins; Indomethacin; Interleukin-6;	1995
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. The Journal of clinical investigation, 1995, Volume: 95, Issue:2 Topics: Abortion, Spontaneous; Animals; Bacterial Infections; Decidua; Dose-Response Relationship, Drug; Enz	1995
Effect of interleukin 2 on the production of progesterone and prostaglandin E2 in human fetal membranes and its consequences for preterm uterine contractions. European journal of endocrinology, 1994, Volume: 130, Issue:5 Topics: Amniotic Fluid; Bacterial Infections; Chorioamnionitis; Culture Techniques; Dinoprostone; Extraembry	1994
Autoregulation of hepatic macrophage activation in sepsis. The Journal of trauma, 1993, Volume: 34, Issue:4 Topics: Bacterial Infections; Cells, Cultured; Dinoprostone; Dose-Response Relationship, Drug; Homeostasis;	1993
Effect of low dose recombinant interleukin 2 plus indomethacin on mortality after sepsis in a murine burn model. The British journal of surgery, 1990, Volume: 77, Issue:4 Topics: Animals; Bacterial Infections; Burns; Disease Models, Animal; Drug Therapy, Combination; Indomethaci	1990
The therapeutic potential of interleukin-1 beta in the treatment of chemotherapy- or radiation-induced myelosuppression and in tumor therapy. Biotherapy (Dordrecht, Netherlands), 1989, Volume: 1, Issue:4 Topics: Animals; Antineoplastic Agents; Bacterial Infections; Bone Marrow; Combined Modality Therapy; Diseas	1989
[The use of indomethacin in acute intestinal infections]. Vrachebnoe delo, 1989, Issue:4 Topics: Acute Disease; Bacterial Infections; Child, Preschool; Convalescence; Dinoprost; Drug Evaluation; Hu	1989
Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet (London, England), 1987, Feb-14, Volume: 1, Issue:8529 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Critical Care; Humans; Hypoxia;	1987
Indomethacin and arterial oxygenation in critically ill patients with severe bacterial pneumonia. Lancet (London, England), 1987, Mar-28, Volume: 1, Issue:8535 Topics: Arteries; Bacterial Infections; Critical Care; Humans; Indomethacin; Lung; Microcirculation; Oxygen;	1987
Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus. Lancet (London, England), 1987, Apr-25, Volume: 1, Issue:8539 Topics: Bacterial Infections; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem	1987
Further evidence that accelerated muscle protein breakdown during sepsis is not mediated by prostaglandin E2. Annals of surgery, 1988, Volume: 207, Issue:4 Topics: Animals; Bacterial Infections; Dinoprostone; Indomethacin; Male; Muscle Proteins; Muscles; Prostagla	1988
Indomethacin-associated sepsis in very-low-birth-weight infants. American journal of diseases of children (1960), 1988, Volume: 142, Issue:5 Topics: Bacterial Infections; Blood Bactericidal Activity; Cell Movement; Chemotaxis, Leukocyte; Ductus Arte	1988
Effects of indomethacin and leupeptin on muscle cathepsin B activity and protein degradation during sepsis. The Journal of surgical research, 1988, Volume: 45, Issue:1 Topics: Animals; Bacterial Infections; Cathepsin B; Indomethacin; Leupeptins; Muscle Proteins; Muscles; Olig	1988

indomethacin and Bacterial Disease